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Synthesis of β2-adrenoreceptor agonist bronchodilator (R)-Salmeterol has been described with good yields. The 
synthesis commenced from commercially available starting materials, 4-hydroxy benzaldehyde and phenylbutanoic acid. 
The features of the synthetic strategy are Wittig olefination and Sharpless asymmetric dihydroxylation. 
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Adrenergic agents, Norepinephrine, Epinephrine, 
Dopamine and (R)-Salmeterol (Figure 1), which 
modulates various processes like rate and force of cardiac 
retrenchment, restriction, dilation of blood vessels and 
bronchioles and many
1,2
. The catecholamines, mediates 
several functions via α-(α1,α2) and β-(β1,β2,β3)-receptors as 
mentioned in the super family of G-protein coupled 
receptors (GPCR’s)
3,4
. Preferentially, (R)-isomer of many 
adrenergic agents have high affinity to bind over 
corresponding adrenoreceptors, because, these are 
biosynthesized in the body from L-tyrosine and thus 
responsible for their biological activity. 
In spite of other bronchodilators, (R)-Salmeterol is 
more potent, long acting, β2-adrenergic, agonist used 
in first line for the treatment of pulmonary diseases 
like bronchospasm, chronic obstructive pulmonary 
and also resistant to both COMT (catechol-o-methyl 
transferase) and MAO (mono amino oxidase)
5-7
. 
Pertaining to its unique properties, attracted the 
attention of synthetic chemists and lead to its 
synthesis in different ways
8-20
. 
Results and Discussion 
As part of our regular research program, in 
synthesis of biologically active natural and synthetic 
molecules
21-25
, herein we report the enantioselective 
synthesis of bronchodilating agent (R)-Salmeterol. 
Retro synthetic analysis (Scheme I) reveals that the 
molecules could be assembled via coupling of two 
important building blocks, in which amine fragment (9) 
could be accessed from commercially available, 
4-hydroxybenzaldehyde (2) and halo fragment (12) 
could be resulted from phenyl butanoic acid (10), on 
reduction followed by coupling with 1,6-
dibromohexane. The pharmacophoric key precursor, 
chiral α-amino alcohol (9) synthesis, started from 4-
hydroxy benzaldehyde (2), which on phenolic Aldol 
condensation
26
 with formaldehyde in presence of base to 
give, 4-hydroxy-3 (hydroxymethyl)benzaldehyde (3) in 
excellent yields. Further, acetonide protection (4), 




benzo[d][1,3]dioxine (5) as shown in the Scheme II
 27-29
. 




β, to afford the key intermediate, chiral diol 6, in 94% 
yield, with 98% ee, confirmed by HPLC data (chiracel 
OD-H). The diol was subjected to selective protection of 
primary alcohol
32,33
 using TsCl and TEA to afford, 
compound 7 in very good yields. Thus obtained tosyl 
was converted into azide through nucleophilic substi 
tution with NaN3 in DMF to give, compound 8, and 
subsequent reduction of azide with Pd/C (10%)
34
 under 
hydrogen atmosphere to give the chiral amino alcohol 
(9) in 88% yield, as shown in the Scheme II.
The second fragment was synthesized from phenyl
butanoic acid (10), which on reduction with LAH to 
give 4-phenylbutan-1-ol (11) in good yields
35,36
. The 
obtained primary alcohol on coupling with 1,6-dibromo 
hexane in presence of K2CO3 resulted, {4[(6-bromo 
hexyl)oxy] butyl} benzene (12) in 65% yields. The key 
fragments 9 and 12 on coupling gives the core 
compound 13 in 85% yields. Finally, the acetonide 
————— 
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deprotection
 
was achieved smoothly in presence of 
acetic acid - water mixture to give the target 
molecule, (R)-Salmeterol (1) in excellent yields and 
selectivity, as shown in the Scheme III. 
Experimental Section 
All the air and moisture sensitive reactions were 
carried out under nitrogen atmosphere. Oven-dried 









Freshly distilled anhydrous solvents were used for air 
and moisture sensitive reactions. Commercially 
available reagents were used as such. Purification of 
compounds was carried out via column 
chromatography by using silica gel (60-120 mesh) 
packed in glass columns. 
1
H NMR and 
13
C NMR were 
recorded in CDCl3 on 400 MHz and 500 MHz 
spectrometer, using TMS as an internal standard. IR 
spectra were recorded on a Perkin-Elmer FT-RT 240-
c Spectrophotometer using KBr / Thin Film optics. 
Mass spectra were recorded on a Finnigan MAT 1020 
mass spectrometer operating at 70eV. Optical rotation 
values were recorded on Horiba sepa300 polarimeter. 
High resolution mass spectra (HRMS) [ESI+] were 




To a stirred solution of 4-hydroxy benzaldehyde (10 
g, 89.3 mmol), in water (80 mL) was added borax (25 g) 
and NaOH solution (1M, 60 mL) and stirred for 30 
minutes at RT. Then aqueous formaldehyde (40%, 10 
mL) was added in one portion. The reaction was stirred 
at 40°C for 5 days. After completion of the reaction 
(monitored by TLC) cooled to RT, and mixture was 
acidified with HCl (3M) upto pH 2. Then, extracted with 
ethyl acetate (3×50 mL). The combined organic portions 
was washed brine, dried over Na2SO4 and concentration 
under reduced pressure. The crude compound was 
purified by column chromatography using silica gel  
(60-120 mesh) by eluting with EtOAc-hexane (3:7) 
mixture to gives a pure compound 3 as white solid, in 
11.2 g (83%). Mp: 142 - 143°C.; IR (neat): υ 3311, 3217, 




H NMR (400 MHz, 
CDCl3): δ 9.85 (s, 1H), 7.80 - 7.72 (m, 1H), 7.68 (d, 1H, J 
= 1.9 Hz), 7.60 (d, 1H, J = 1.8 Hz), 7.01 (dd, 1H, J = 8.3, 
3.6 Hz), 4.99 (brs, 1H), 4.87 (s, 2H).; 
13
C NMR (100 
MHz, CDCl3): δ 190.7, 161.1, 132.6, 130.8, 129.6, 122.8, 
117.0, 67.6.; HRMS-ESI: m/z [M-H]
+ 
Calcd for C8H7O3: 




To a stirred solution of compound 3 (5 g, 32.9 mmol) 
in dry acetone (50 mL) was added 2,2-DMP (4.4 g, 42.8 
mmol) and a cat. amount of pTSA, continued stirring for 
1h at RT. After completion of the reaction (monitored by 
TLC), extracted with EtOAc (3×20 mL). The combined 
organic layers were washed with brine, dried over 
Na2SO4 and concentrated under reduced pressure. The 
crude product was purified by column chromatography 
using silica gel (60-120 mesh) by eluting with EtOAc-
hexane (1:9) mixture to obtain compound 4 as yellow 





H NMR (400 MHz, CDCl3): δ 9.86 
(s, 1H), 7.71 (d, 1H, J = 10.3 Hz), 7.55 (s, 1H), 6.93 (d, 
1H, J = 8.4 Hz), 4.91 (s, 2H), 1.58 (s, 6H).; 
13
C NMR 
(100 MHz, CDCl3): δ 190.7, 156.8, 130.5, 129.5, 126.9, 
119.7, 117.7, 100.8, 60.6, 24.8.; HRMS-ESI: m/z 
[M+H]
+ 
Calcd for C11H13O3: 193.0872; found: 193.0927. 
 
2,2-Dimethyl-6-vinyl-4H-benzo[d][1,3]dioxine, 5 
To a stirred suspension of compound 4 (2 g, 10.4 
mmol) in dry THF (15 mL), was added a solution of C1 
ylide salt (21.1 g, 52.1 mmol, THF) and 
t
BuOK (5.8 g, 
10.4 mmol) at 0
°C
 and continued stirring for 2h at RT. 
After completion (monitored by TLC), reaction was 
quenched with cold water, then removed THF under 
vacuum and extracted with EtOAc (3×20 mL). The 
combined organic layers were washed with brine, dried 
over Na2SO4 and concentrated under reduced pressure. 
The crude product was purified by column chromato 
graphy using silica gel (60-120 mesh) by eluting with 
EtOAc-hexane (2:8) mixture to give the compound 5 as 
yellow liquid, in 1.58 g (80%). IR (neat): υ 2991, 2923, 




H NMR (400 MHz, 
CDCl3): δ 7.23 (d, 1H, J = 8.4 Hz), 7.01 (s, 1H), 6.78 
(d, 1H, J = 8.4 Hz), 6.62 (dd, 1H, J =17.3, 10.9 Hz), 5. 
59 (d, 1H, J = 17.3 Hz), 5.12 (d, 1H, J = 10.9 Hz), 4.84 
(s, 2H), 1.54 (s, 6H).; 
13
C NMR (100 MHz, CDCl3): δ 
151.0, 136.1, 130.1, 125.9, 122.4, 119.2, 117.1, 111.7, 
99.6, 60.8, 24.7.; HRMS-ESI: m/z [M+H]
+ 
Calcd for 




To a stirred mixture of 
t
BuOH-H2O (1:1, 63 mL) 
was added compound 5 (1.2 g, 6.3 mmol), then added 
AD-mix-β (8.8 g) followed by methanesulfonamide 
(0.6 g) at 0°C and stirred continuously for 24h at same 
temperature. After the completion of reaction 
indicated by TLC, sodium sulphite (7.5 g) was added. 
The suspension was dissolved in cold water and 
extracted with EtOAc (3×20 mL). The combined 
organic layers were washed with brine, dried over 
Na2SO4 and concentrated under reduced pressure. The 
crude product was purified by column chromato 
graphy using silica gel (60-120 mesh) by eluting with 
EtOAc-hexane (3:7) mixture to give pure compound 6 
as a white solid, in 1.3 g (94%). Mp: 80 - 81°C. 
Specific rotation: [α]D
25
 -11 (c = 1, CHCl3): IR (neat): 









(400 MHz, CDCl3): δ 7.14 (dd, 1H, J = 8.4, 1.8 Hz), 
7.02 (s, 1H), 6.81 (d, 1H, J = 8.43 Hz), 4.84 (s, 2H), 
4.77- 4.72 (m, 1H), 3.78 - 3.69 (m, 1H), 3.68 - 3.60 
(m, 1H), 1.54 (s, 6H).; 
13
C NMR (100 MHz, CDCl3): 
δ 151.0, 132.3, 125.9, 122.4, 119.4, 117.1, 99.6, 74.2, 
68.0, 60.8, 24.7, 24.6.; HRMS-ESI: m/z [M-H]
+ 
Calcd 




To a stirred mixture of 6 (1 g, 4.5 mmol) in dry 
DCM (10 mL) at 0°C was added Bu2SnO (0.2 g, 0.9 
mmol), TsCl (0.85 g, 4.5 mmol) and Et3N (0.67 g, 6.7 
mmol) and stirring continued for 1h. After completion 
of the reaction (monitored by TLC), quenched with 
cold water and extracted with DCM (3×10 mL). The 
combined organic layers were washed with brine, 
dried over Na2SO4 and concentrated under reduced 
pressure. Thus obtained crude compound 7, a yellow 
liquid (1.68 g, 79%), was used for further reaction 
without purification. Specific rotation: [α]D
25
 -3.5 (c = 





H NMR (400 MHz, CDCl3): δ 7.77 
(d, 2H, J = 8.6 Hz), 7.34 (d, 2H, J = 8.6 Hz), 7.07 (dd, 
1H, J = 8.0, 1.8 Hz), 6.95 (d, 1H, J = 1.4 Hz), 6.77 (d, 
1H, J = 8.4 Hz), 4.92 - 4.87 (m, 1H), 4.80 (s, 2H), 
4.14 - 4.09 (m, 1H), 4.05 - 3.99 (m, 1H), 2.45 (s, 
3H).1.52 (s, 6H).; 
13
C NMR (100 MHz, CDCl3): δ 
151.4, 145.0, 132.6, 130.0, 129.9, 127.9, 126.0, 122.6, 
119.6, 117.2, 99.7, 74.2, 71.5, 60.7, 24.8, 24.5, 21.6.; 
HRMS-ESI: m/z [M+Na]
+ 
Calcd for C19H22NaO6S: 
401.1037; found: 401.1045. 
 
(R)-2-Azido-1-(2,2-dimethyl-4H-benzo[d][1,3]dioxin-
6-yl) ethanol, 8 
To a stirred solution of compound 7 (1 g, 2.6 mmol) 
in dry DMF (10 mL) was added NaN3 (0.86 g, 13.2 
mmol) and stirred continuously at 70°C for 12 h. After 
completion of the reaction, confirmed by TLC, extracted 
with EtOAc (3×20 mL). The combined organic layers 
were washed with brine, dried over Na2SO4 and 
concentrated under reduced pressure. The crude product 
was purified by column chromatography using silica gel 
(60-120 mesh) by eluting with EtOAc-hexane (1:9) 
mixture to afford the compound 8 as colorless liquid, in 
0.6 g (92%). Specific rotation: [α]D
25
 -3.3 (c = 1, CHCl3): 




H NMR (400 MHz, CDCl3): δ 7.14 (dd, 1H, J = 8.4, 1.5 
Hz), 7.02 (s, 1H), 6.82 (d, 1H, J = 8.3 Hz), 4.85 (s, 2H), 
4.84 - 4.76 (m, 1H), 3.52 - 3.37 (m, 2H), 1.54 (s, 6H); 
13
C NMR (100 MHz, CDCl3): δ 151.3, 132.3, 125.8, 
122.3, 119.4, 117.3, 99.7, 73.0, 60.8, 58.1 24.7, 24.6.; 
HRMS-ESI: m/z [M+Na]
+ 
Calcd for C12H15N3 NaO3: 
272.1011; found: 272.1025. 
 
(R)-2-Amino-1-(2,2-dimethyl-4H-benzo[d][1,3]dioxin-
6-yl) ethanol, 9 
To the compound 8 (0.5 g, 2 mmol) in ethyl acetate 
(10 mL) was added catalytic amount of Pd/C (10%) 
and stirred under hydrogen atmosphere at RT, 12h. 
After completion of the reaction, indicated by TLC, 
filtered through celite bed. The filtrate was dried over 
Na2SO4 and concentrated under reduced pressure, the 
obtained crude compound 9 as half-white solid, in 0.4 
g (88%) and which was used for further reaction 
without purification. Specific rotation: [α]D
25
 -2.5 (c = 





H NMR (400 MHz, DMSO): δ 7.10 (d, 1H, J = 
8.4 Hz), 7.01 (s, 1H), 6.73 (d, 1H, J = 8.2 Hz), 4.88 - 
4.82 (m, 1H), 4.80 (s, 2H), 4.45 - 4.37 (m, 2H), 1.77 
(s, 2H), 1.45 (s, 6H).; 
13
C NMR (100 MHz, CDCl3): δ 
149.5, 135.8, 125.6, 122.4, 118.9, 115.9, 99.0, 73.1, 
60.1, 49.3, 24.5, 24.4.; HRMS-ESI: m/z [M+Na]
+ 
Calcd for C12H17NNaO3: 246.1104; found: 246.1117. 
 
4-Phenylbutan-1-ol, 11 
To a stirred solution of 4-phenylbutyric acid (2 g, 
12.2 mmol) in dry THF (20 mL) was added LAH 
(0.66g, 18.3 mmol) at 0°C and the reaction mixture 
was stirred for 1h at RT. After completion of the 
reaction, as indicated by TLC, then quenched with 
ammonium chloride solution and solvent was 
removed under reduced pressure. The residue was 
extracted with EtOAc (3×20 mL) and the combined 
organic layers were washed with brine, dried over 
Na2SO4 and concentrated under vacuum. The crude 
product was purified by column chromatography 
using silica gel (60-120 mesh) by eluting with EtOAc-
hexane (1:9) mixture to give the pure compound 11 as 
yellow liquid, in 1.3 g (75%). IR (neat): υ 3745, 3350, 




H NMR (400 MHz, 
CDCl3): δ 7.30 - 7.23 (m, 2H), 7.21 - 7.12 (m, 3H), 
3.63 (t, 2H, J = 6.4 Hz), 2.63 (t, 2H, J = 7.3 Hz), 1.73 
- 1.64 (m, 2H), 1.63 - 1.54 (m, 2H).; 
13
C NMR (100 
MHz, CDCl3): δ 142.2, 128.4, 128.2, 125.9, 125.6, 
62.6, 35.5, 32.1, 27.4.; HRMS-ESI: m/z [M-H]
+ 
Calcd 
for C10H13O: 149.1044; found: 149.1059. 
 
[4-(6-Bromohexyloxy)butyl] benzene, 12 
To a stirred solution of compound 11 (1 g, 6.7 m 
mol) in dry acetonitrile (20 mL) was added 1,6-di 
bromohexane (0.54 g, 2.3 mmol) followed by K2CO3 
(0.1 g, 0.67 mmol) and KI (0.11 g, 0.67 m mol) at RT. 




The reaction mixture was stirred for 7h at 80°C. After 
completion of reaction (confirmed by TLC), the 
reaction mixture was concentrated and residue was 
diluted with cold water and extracted with EtOAc 
(3×20 mL). The combined organic layers, washed with 
brine, dried over Na2SO4 and concentrated. The crude 
product, purified by column chromatography using 
silica gel (60-120 mesh) by eluting with EtOAc-hexane 
(2:8) mixture to afford the compound 12 as yellow 
liquid, in 1.3 g (65%). IR (neat): υ 3044, 2928, 2843, 




H NMR (400 MHz, 
CDCl3): δ 7.32 - 7.25 (m, 2H), 7.22 - 7.15 (m, 3H), 
4.06 (t, 2H, J = 6.6 Hz), 3.18 (t, 2H, J = 6.9 Hz), 2.65 
(t, 2H, J = 7.4 Hz), 2.32 (t, 2H, J = 7.3 Hz), 2.02 - 1.91 
(m, 2H), 1.87 - 1.76 (m, 2H), 1.68 - 1.57 (m, 4H), 1.50 
- 1.29 (m, 4H).; 
13
C NMR (100 MHz, CDCl3): δ = 
147.3, 128.4, 128.3, 125.9, 64.1, 35.1, 33.6, 33.2, 32.5, 
30.0, 28.4, 27.7, 26.5, 24.9.; HRMS-ESI: m/z [M+Na]
+ 




To a stirred mixture of compound 9 (0.3 g, 1.34 m 
mol) and K2CO3 (400 mg, 2.89 mmol) in dry aceto 
nitrile (10 mL) at r. t., was added compound 12 (0.25 g, 
0.8 mmol) and continued stirring for 48h at 80°C. TLC 
confirms the completion of reaction and then the 
reaction mixture was concentrated and residue was 
dissolved in water and extracted with EtOAc (3×10 
mL). The combined organic layers, washed with brine, 
dried over Na2SO4 and concentrated under reduced 
pressure to obtained the crude compound 13 as yellow 
liquid, in 0.5 g (85%). Specific rotation: [α]D
25
 -11.6  
(c = 1, CHCl3).; IR (neat): υ 3445, 3052, 2926, 1632, 




H NMR (400 
MHz, CDCl3): δ 7.30 - 7.27 (m, 1H), 7.20 - 7.16 (m, 
4H), 7.08 (dd, 1H, J = 8.4, 2.0 Hz), 6.88 (s, 1H), 6.80 (d, 
1H, J = 8.4 Hz), 4.88 - 4.84 (m, 1H), 4.83 (s, 2H), 3.66 
(t, 4H, J = 6.4 Hz), 3.13 - 3.10 (m, 1H), 2.80 - 2.77 (m, 
1H), 2.65 (t, 4H, J = 7.4 Hz), 1.74 - 1.56 (m, 8H), 1.53 (s, 
6H), 1.42 - 1.32 (m, 4H).; 
13
C NMR (100 MHz, CDCl3): δ 
151.2, 142.2, 129.1, 128.3, 128.2, 125.7, 125.5, 121.7, 
119.5, 117.2, 99.6, 70.6, 62.7, 60.8, 60.3, 52.1, 50.9, 35.7, 
35.6, 32.2, 29.6, 29.3, 28.0, 27.5, 24.7, 24.6.; HRMS-ESI: 
m/z [M+Na]
+ 





To a stirred solution of acetic acid (4 mL) and water 
(2 mL) was added the compound 13 (50 mg, 0.1mmol) 
and stirred at 70°C for 1h. The completion of reaction 
was confirmed by TLC. The reaction mixture was 
neutralized by adding sat. NaHCO3. Then reaction 
mixture extracted with EtOAc (3×20 mL), the combined 
organic layers were washed with brine, dried over 
Na2SO4 and concentrated under reduced pressure, to 
obtain the crude product, which was recrystalized with 
ethyl acetate to yield pure product as solid, in 40 mg 
(88%). Mp: 75 - 76°C [lit,
17
 75 - 76°C]. Specific 
rotation: [α]D
25





(c = 1, CHCl3).; IR (neat): υ 3443, 3048, 2929, 1627, 





(400 MHz, CDCl3): δ 7.27 - 7.22 (m, 2H), 7.19 - 7.12 
(m, 3H), 6.95 (s, 1H), 6.84 (d, 1H, J = 7.4 Hz), 6.67 (d, 
1H, J = 7.4 Hz), 4.88 - 4.68 (m, 3H), 4.43 (s, 2H), 3.38 
(t, 2H, J = 6.4 Hz), 3.33 (t, 2H, J = 6.4 Hz), 2.91 - 2.79 
(m, 2H), 2.59 (t, 4H, J = 7.2 Hz), 1.72 - 1.54 (m, 6H), 
1.53 - 1.45 (m, 2H), 1.36 - 1.15 (m, 4H).; 
13
C NMR (100 
MHz, CDCl3): δ 155.1, 142.3, 130.9, 128.3, 128.2, 
126.7, 126.3, 125.6, 115.8, 70.7, 70.6, 68. 6, 61.0, 54.1, 
48.0, 35.6, 29.6, 29.4, 29.2, 27.9, 26.4, 25.8, 25.6, 22.8.; 
HRMS-ESI: m/z [M+H]
+ 
Calcd for C25H38NO4: 
416.27954; found: 416.28009. 
 
Conclusions 
In summary, we have accomplished the enantio 
selective synthesis of β2-agonist, (R)-Salmeterol 
successfully. The synthesis comprises, a simple, facile 
and inexpensive methodologies, in good yields with an 
overall yield of 9.5 % in 11 steps. The required chiral 
center in pharmacophore was fixed using Sharpless 
asymmetric dihydroxylation protocol. 
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